Pharma Life Cycle Management (LCM) in France is the discipline of extending a product's value after launch, well beyond patent defense. It combines indication extensions, new dosage forms, Rx-to-OTC switches, regional rollouts, brand repositioning, and defense against generics. In France, LCM is shaped by a tight regulatory frame (ANSM, HAS, CEPS) and is won or lost on operational execution, not on PowerPoint strategy. Stryke Consulting supports laboratories on this discipline as a fractional healthcare operator — C-level thinking, hands-on execution, 360° view of the product life cycle.
Three recurring biases explain why LCM stays a poor cousin in many organizations.
The launch bias. Management attention concentrates on launch readiness. Once the promotional peak passes, the product loses its sponsors and shifts into maintenance mode. Yet 60 to 80 percent of a pharma asset's cumulative value is captured after launch, not before.
The regulatory bias. Many LCM plans collapse into label extensions or variation dossiers. That is necessary but insufficient. An LCM that does not touch the marketing mix, medical training, prescription channels and pricing strategy leaves value on the table.
The consulting bias. LCM is often outsourced to a consultancy that produces a strategic deck. The deck lands in a shared drive, execution falls back on already-saturated internal teams, and the plan unravels within six months.
Identify under-treated subpopulations or adjacent indications where the mechanism of action remains clinically relevant. The operational question is not "can we extend the label?" but "who prescribes today, who should prescribe tomorrow, and what clinical pathway connects the two?". Answered jointly by medical, marketing, and market access — not in a regulatory silo.
Extended-release tablets, pediatric formulations, ready-to-use devices, hospital packs. A well-chosen new form creates a new value proposition without requiring a new molecule. For Cooper on Betadine, this lever is central: the brand lives as much through the diversity of its formats as through the molecule itself.
When the pharmacovigilance history allows, a switch opens an officinal distribution channel and redefines the patient relationship. It is also one of the most complex levers: it touches pricing, patient education, pharmacist training, positioning vs OTC competitors, and merchandising.
A generic launch does not erase the brand. Defense levers include perceived quality, prescriber loyalty, patient services, adherence programs, and differentiation through formulation or packaging. The most common mistake is waiting for LOE day to react.
A mature product can find new traction with a refreshed brand brief, a redesigned communication architecture, or repositioning by prescriber segment. This lever is often neglected because it sits outside the strict regulatory frame — which is precisely why it creates value.
Phase 1 — 360° diagnostic (3 to 6 weeks). Read of the portfolio, available prescription data, regulatory dossiers, sales force plans, and field feedback. Identification of three to five high-signal levers and the ones to drop.
Phase 2 — Bet framing (2 to 4 weeks). The LCM bets are picked with sponsors from the business unit, medical, market access and regulatory. Decisions are explicit: what gets done, what does not, what gets done later. Trade-offs are documented.
Phase 3 — Hands-on execution (12 to 24 months). Co-construction of regulatory dossiers, creative briefs, communication plans, training modules, and regional rollout calendars. Weekly steering meetings. Stryke does not arrive with a deliverable; Stryke sits in the room with the teams.
Phase 4 — Measurement and feedback loop (continuous). Clear KPIs on share of voice, prescription, pharmacy coverage, and prescriber NPS. Short-cycle feedback loop with the business unit to adjust.
Stryke runs the Betadine LCM for Cooper, oversees a second major consumer health portfolio product, and assumes the PMO function across the portfolio. The mission combines all five levers: line extensions, market share defense under competitive pressure, cross-functional coordination across medical, regulatory, marketing and supply, and PMO support. The fractional operator format gives Cooper teams sustained C-level capacity without opening a full-time role.
For commercial confidentiality reasons, detailed KPIs are not published. The extended case study is available on request, under NDA.
Confusing LCM with the annual tactical plan. LCM is a 24- to 36-month horizon. The annual plan executes LCM milestones, it does not replace them.
Outsourcing LCM to a single function. An LCM owned only by marketing, only by medical, or only by regulatory will fail. By construction, it is a cross-functional exercise.
Ignoring prescriber voice. The best LCM bets often emerge from weak signals surfaced by sales reps and key opinion leaders. Build a structured loop to capture them.
Launching without a measurement frame. Without KPIs defined before go, the value of LCM is impossible to defend in front of executive management. And an LCM that cannot be defended is an LCM cut at the next budget round.
Three situations justify the move.
The organization has no business unit dedicated to portfolio maturity, and LCM falls between the cracks. A fractional operator owns the mission, no full hire required.
Internal expertise exists, but C-level capacity is consumed by launches and corporate topics. The fractional unblocks critical bandwidth.
The context calls for an outside perspective armed with cross-laboratory experience, without the deliverable format of a consultancy. The fractional operates in the room, not in a final presentation.
What is pharma Life Cycle Management in France?
Pharma LCM covers the strategic and operational moves that extend a product's value after launch: indication extensions, new dosage forms, Rx-to-OTC switches, line extensions, brand repositioning, and defense against generics. In France, it operates within a tight regulatory frame governed by ANSM, CEPS for pricing, and HAS for reimbursement.
When should an LCM plan kick off in a pharma product's life?
An LCM plan should be in motion 24 to 36 months before loss of exclusivity or before a known competitor enters. Market maturity, prescription trajectory, and competitive signals trigger the decision more than a fixed date.
What is the difference between strategic and operational LCM?
Strategic LCM picks the bets: which indications, which formats, which geographies. Operational LCM executes: regulatory dossiers, creative briefs, sales force plans, training, regional rollouts. Without the second, the first stays a PowerPoint.
Why hire a fractional operator instead of a consulting firm?
A consultancy delivers recommendations. A fractional operator delivers decisions, trade-offs, and execution aligned with internal teams. On an LCM that runs 12 to 36 months, sustained presence in the room outperforms a final report.
Does Stryke Consulting have a concrete LCM reference?
Yes. Stryke runs the Betadine LCM for Cooper, oversees a second major portfolio product, and acts as PMO for the consumer health portfolio.